Scott Burian

Rho, Inc.
Senior Scientist
Dr. Burian is a broadly-experienced regulatory affairs professional specializing in pharmaceutical development, regulatory strategy, and chemistry, manufacturing, and controls (CMC). Prior to joining Rho in early 2016, he served most recently as a Director, Regulatory Affairs CMC at Mallinckrodt Pharmaceuticals. In this role he authored CMC related documentation for regulatory submissions, provided input on regulatory strategies related to CMC, participated in FDA interactions, and performed man-in-the-plant activities at contract manufacturing organizations. Prior to Mallinckrodt Pharmaceuticals, Dr. Burian held Director of CMC Regulatory Affairs positions at Kowa Research Institute and Cato Research from 2002 through 2015.